Precipio achieves two of three 2023 goals; revenue up ~50% YoY, cash burn cut 60%

Precipio, Inc.

Pathology division hit $14M annualized revenue in Q3, meeting target #1; product target lowered to $6M.
Quarterly cash burn reduced from $2.5M (Q3-2022) to $1M (Q3-2023), exceeding target #3.
Q3 2023 total revenue $4.5M (50% YoY gain); annualized run-rate ~$18.5M.
Expects Q4 2023 revenue $3.2-$3.5M, FY 2023 total ~$14.5M vs $9.8M in 2022.
If ~50% growth continues, positive cash flow possible in H2 2024 at ~$30M annual run-rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.